Table 2.
Heart rate (b.p.m.) at baseline (before any intervention), after pretreatment, after rilmenidine and with adrenaline (at the onset of arrhythmias)
| Dose of rilmenidine (μg kg−1, IC) | n | Baseline | After pretreatment | After rilmenidine | With adrenaline |
|---|---|---|---|---|---|
| Experiment 1 | |||||
| 0 | 8 | 320±17 | 318±31 | 390±46 | |
| 0.01 | 8 | 317±29 | 318±30 | 405±52 | |
| 0.05 | 8 | 303±18 | 303±15 | 391±39 | |
| 0.1 | 8 | 307±43 | 289±43 | 400±42 | |
| Experiment 2:rilmenidine+vagotomy | |||||
| 0.1 | 8 | 327±16 | 354±26*,** | 338±17 | 442±39 |
| Experiment 2: rilmenidine+atropine methylnitrate | |||||
| 0.1 | 8 | 325±22 | 351±11*,** | 342±13 | 415±36 |
| Experiment 3: rilmenidine+calphostin C | |||||
| 0 | 8 | 311±39 | 323±31 | 317±34 | 392±23 |
| 0.1 | 8 | 301±50 | 313±43 | 318±26 | 385±35 |
| Experiment 4: rilmenidine+5-HD | |||||
| 0 | 7 | 312±32 | 319±26 | 324±27 | 399±55 |
| 0.1 | 7 | 325±14 | 320±25 | 319±44 | 372±33 |
| Experiment 4: rilmenidine+HMR-1098 | |||||
| 0 | 7 | 316±33 | 333±33 | 349±38 | 400±62 |
| 0.1 | 6 | 320±14 | 327±21 | 328±20 | 443±48 |
| Experiment 5: rilmenidine+atractyloside | |||||
| 0 | 8 | 312±13 | 313±25 | 318±30 | 386±67 |
| 0.1 | 8 | 290±18 | 307±40 | 297±36 | 348±47 |
Abbreviation: 5-HD, 5-hydroxydecanoic acid.
*P<0.05, compared with the value at baseline.
**P<0.05, compared with corresponding value without rilmenidine.
Data are mean (±s.d.) values from the number of assays shown.